MX393452B - Tratamiento de los trastornos depresivos. - Google Patents
Tratamiento de los trastornos depresivos.Info
- Publication number
- MX393452B MX393452B MX2019014024A MX2019014024A MX393452B MX 393452 B MX393452 B MX 393452B MX 2019014024 A MX2019014024 A MX 2019014024A MX 2019014024 A MX2019014024 A MX 2019014024A MX 393452 B MX393452 B MX 393452B
- Authority
- MX
- Mexico
- Prior art keywords
- depressive disorders
- treatment
- treating depressive
- disorders
- gaboxadol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510481P | 2017-05-24 | 2017-05-24 | |
| US15/933,673 US20180338959A1 (en) | 2017-05-24 | 2018-03-23 | Treatment of depressive disorders |
| PCT/US2018/033848 WO2018217718A1 (en) | 2017-05-24 | 2018-05-22 | Treatment of depressive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019014024A MX2019014024A (es) | 2020-02-17 |
| MX393452B true MX393452B (es) | 2025-03-24 |
Family
ID=64395877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014024A MX393452B (es) | 2017-05-24 | 2018-05-22 | Tratamiento de los trastornos depresivos. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20180338959A1 (https=) |
| EP (2) | EP3939587A1 (https=) |
| JP (2) | JP2020520963A (https=) |
| KR (1) | KR20200018485A (https=) |
| CN (2) | CN115105499A (https=) |
| AU (1) | AU2018272819A1 (https=) |
| CA (1) | CA3064299A1 (https=) |
| IL (1) | IL270781A (https=) |
| MX (1) | MX393452B (https=) |
| WO (1) | WO2018217718A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| US10987303B2 (en) * | 2018-05-02 | 2021-04-27 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| AU2020223284A1 (en) | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| KR102085938B1 (ko) * | 2019-11-04 | 2020-03-06 | 한국메탈실리콘 주식회사 | 실리콘 복합체 제조방법 |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270378A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| BRPI0410857A (pt) * | 2003-06-25 | 2006-07-04 | Lundbeck & Co As H | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica |
| JP2007530604A (ja) | 2004-04-02 | 2007-11-01 | ハー・ルンドベック・アクチエゼルスカベット | 呼吸機能障害の治療 |
| US20090048288A1 (en) * | 2007-08-13 | 2009-02-19 | H. Lundbeck A/S | Method of treating stress-mediated depression |
| US10628156B2 (en) * | 2013-07-09 | 2020-04-21 | Texas Instruments Incorporated | Vector SIMD VLIW data path architecture |
| RS62007B1 (sr) * | 2014-06-06 | 2021-07-30 | Ovid Therapeutics Inc | Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma |
| EP4541420A3 (en) * | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| WO2017027249A1 (en) * | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| AU2020313930A1 (en) * | 2019-07-15 | 2022-02-03 | Ovid Therapeutics Inc. | Pharmaceutical formulations containing gaboxadol for therapeutic treatment |
-
2018
- 2018-03-23 US US15/933,673 patent/US20180338959A1/en not_active Abandoned
- 2018-05-22 EP EP21195602.4A patent/EP3939587A1/en not_active Withdrawn
- 2018-05-22 EP EP18805653.5A patent/EP3630065A4/en not_active Withdrawn
- 2018-05-22 WO PCT/US2018/033848 patent/WO2018217718A1/en not_active Ceased
- 2018-05-22 MX MX2019014024A patent/MX393452B/es unknown
- 2018-05-22 CN CN202210735249.1A patent/CN115105499A/zh active Pending
- 2018-05-22 CA CA3064299A patent/CA3064299A1/en active Pending
- 2018-05-22 AU AU2018272819A patent/AU2018272819A1/en not_active Abandoned
- 2018-05-22 JP JP2019564822A patent/JP2020520963A/ja active Pending
- 2018-05-22 CN CN201880048161.4A patent/CN110996910A/zh active Pending
- 2018-05-22 KR KR1020197038042A patent/KR20200018485A/ko not_active Ceased
- 2018-12-18 US US16/223,356 patent/US20190117633A1/en not_active Abandoned
-
2019
- 2019-11-20 IL IL270781A patent/IL270781A/en unknown
-
2020
- 2020-02-19 US US16/794,354 patent/US20200179351A1/en not_active Abandoned
-
2021
- 2021-08-18 US US17/405,525 patent/US20210379028A1/en not_active Abandoned
-
2023
- 2023-01-25 JP JP2023009149A patent/JP2023061957A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20180338959A1 (en) | 2018-11-29 |
| EP3630065A1 (en) | 2020-04-08 |
| US20200179351A1 (en) | 2020-06-11 |
| JP2023061957A (ja) | 2023-05-02 |
| MX2019014024A (es) | 2020-02-17 |
| JP2020520963A (ja) | 2020-07-16 |
| CA3064299A1 (en) | 2019-11-29 |
| AU2018272819A1 (en) | 2019-12-05 |
| EP3939587A1 (en) | 2022-01-19 |
| CN115105499A (zh) | 2022-09-27 |
| CN110996910A (zh) | 2020-04-10 |
| EP3630065A4 (en) | 2021-03-24 |
| WO2018217718A1 (en) | 2018-11-29 |
| US20190117633A1 (en) | 2019-04-25 |
| US20210379028A1 (en) | 2021-12-09 |
| IL270781A (en) | 2020-01-30 |
| KR20200018485A (ko) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393452B (es) | Tratamiento de los trastornos depresivos. | |
| CY1124368T1 (el) | Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman | |
| IL283325A (en) | Methods for treatment using adoptive cell therapy | |
| IL272444A (en) | Compounds, their salts and methods for treating diseases | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| EP3720553C0 (en) | PHOTOBIOMODULATION DEVICE FOR THE TREATMENT OF A RETINAL DISEASE | |
| IL257663B (en) | Oral care compositions and methods of use | |
| ZA201807438B (en) | Methods of treating ocular conditions | |
| MX385578B (es) | Moduladores de canales de kv3 para tratar dolor. | |
| IL281736A (en) | Methods of treating myeloproliferative disorders | |
| EA202090180A1 (ru) | Композиции nk1-антагониста и способы лечения депрессии | |
| ZA201703467B (en) | Methods of treating ocular conditions | |
| LT4034122T (lt) | Hiperfenilalaninemijos gydymo būdai | |
| PL3952858T3 (pl) | Sposób leczenia guzów | |
| IL290983A (en) | Treatment methods | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| IL289436A (en) | Methods for treating ocular diseases | |
| IL281589A (en) | Methods of treating myeloproliferative disorders | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| IL281839A (en) | Treatment methods | |
| IL281792A (en) | Treatment methods | |
| IT201700104446A1 (it) | Compositions, uses and methods for treatment of infertility and subfertility | |
| EP3996644A4 (en) | MULTI-AGENT OCULAR FORMULATIONS AND METHODS OF TREATMENT | |
| EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга | |
| DK4054582T3 (da) | Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter |